Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.

Date publication

février 2022

Journal

Gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
D'Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35122766

Résumé

Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. SERENE CD evaluated higher vs standard adalimumab induction dosing and clinically adjusted (CA) vs therapeutic drug monitoring (TDM) maintenance strategies in patients with moderately to severely active CD.

Mots clés

Biologic agent, TNF inhibitor, inflammatory bowel disease, monoclonal antibody

Référence

Gastroenterology. 2022 Feb 2;: